Royalty bearing license agreement to commercialise a product incorporating the Affimer technology Wetherby and Cambridge, UK, 10 October 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has agreed a commercial license with New England Biolabs® (NEB®) (Ipswich MA, USA), a global leader in the discovery and production of enzymes [...]

Funding to support commercialization of ExoView™ system BOSTON--NanoView Biosciences, an emerging leader in the field of exosome detection and characterization, today announced the closing of a $10 million Series B financing led by Northpond Ventures. Existing investors, including Sands Capital Ventures and PBM Capital Group, participated in the financing round. Proceeds will be used to [...]

Label individual cells with uniquely identifiable, expressed barcodes to understand how different experimental conditions affect distinct groups of cells from a common progenitor MOUNTAIN VIEW, Calif. -- Cellecta, Inc. today introduced the CloneTracker XP™ Expressed Lentiviral Barcode Library and CloneTracker XP™ Barcoded CRISPR Library product lines. The ability to label and trace individual cells is a powerful experimental [...]

SAN DIEGO – Maravai LifeSciences, a leader in providing reagents to researchers, biotherapeutics manufacturers and OEM partners worldwide, today announced that it has hired Christopher Shaffer as senior director of oligonucleotide process development for TriLink BioTechnologies. In this new position, Shaffer will develop and refine processes that improve overall efficiency and will be instrumental when TriLink [...]

HUNTSVILLE, Ala.--The first hyperspectral images from the German Aerospace Center (DLR) Earth Sensing Imaging Spectrometer (DESIS) Hyperspectral Imager have been received and transmitted back to Earth from the International Space Station (ISS). The imager, designed by DLR, is the first payload hosted aboard the Teledyne (NYSE:TDY) Multi-User System for Earth Sensing (MUSES) platform. DESIS is [...]

Cambridge, UK – Abcam’s new phosphate buffered saline (PBS)-only recombinant antibodies are free from preservatives and stabilising agents, offering improved flexibility for researchers conducting more complex experiments. Typically, antibodies are stored in a buffer composed of bovine serum albumin (BSA), glycerol and sodium azide to ensure stability. However, these components can inhibit effective conjugation to certain [...]

WAKEFIELD, Mass.--Genetics Research LLC, an inventor of innovative technologies for the development of products for genomic analysis in research, diagnostics, and therapeutics, announced today that the U.S. Patent and Trademark Office granted the Company U.S. Patent No. 10,081,829, entitled "Detection of targeted sequence regions.” The patent covers a novel method for enriching sequence specific nucleic [...]

Menlo Park, CA – Personalis, Inc., a provider of advanced genomic sequencing and analytics for immuno-oncology, today announced an extension to their contract with the US Department of Veterans Affairs (VA) to sequence a further 34,000 whole human genomes for the VA’s Million Veteran Program (MVP).  This brings the total of all Personalis contracts from [...]

The former AkzoNobel Specialty Chemicals is today being relaunched as Nouryon. The move follows the recent acquisition of the business by The Carlyle Group and GIC and marks the company’s transition to becoming an independent, global specialty chemicals leader. “Launching our new company is a significant milestone to add to our proud history and we [...]

FUJISAWA CITY, Japan & DUBLIN--GenAhead Bio Incorporated (“GenAhead”) and ERS Genomics Limited (“ERS Genomics”) announced today a non-exclusive license agreement to provide GenAhead with access to ERS Genomic’s CRISPR/Cas9 genome editing technology patents. ERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, co-inventor of the breakthrough gene editing technology. GenAhead had its start [...]